Prevnar 13 poised for wider paediatric market
This article was originally published in Scrip
Executive Summary
Pfizer is set to file for expanded approval of its pneumococcal vaccine Prevnar 13 in the US, EU and other markets on the basis of new Phase III data in children aged between five and 17 years.